Final overall survival (OS) with talazoparib (TALA) + enzalutamide ...
1 day ago · Background: The Phase 3 TALAPRO-2 trial met its primary endpoint, showing improved radiographic progression-free survival (rPFS) for TALA + ENZA vs placebo (PBO) + …
177Lu-PSMA-617 Improves Upon Enzalutamide in mCRPC
4 days ago · Adding 177 Lu-PSMA-617 to enzalutamide improves survival and quality of life in patients with metastatic castration-resistant prostate cancer (mCRPC) who are at risk of early …
Mevrometostat (PF-06821497) in combination with enzalutamide …
1 day ago · Background: Resistance to androgen receptor (AR) pathway inhibitors (ARPI; e.g., abiraterone, enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) may be …
Final overall survival (OS) with talazoparib (TALA) + enzalutamide ...
1 day ago · Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line (1L) treatment in patients (pts) with homologous recombination repair (HRR)-deficient …
An update on enzalutamide in the treatment of prostate cancer
In the randomized phase III AFFIRM study, significant improvements in survival versus placebo were observed when enzalutamide was used as a treatment for patients with metastatic …
Talazoparib plus enzalutamide in men with first-line metastatic ...
Jul 22, 2023 · We aimed to compare the efficacy and safety of talazoparib (a PARP inhibitor) plus enzalutamide (an androgen receptor blocker) versus enzalutamide alone in patients with …
Continuous enzalutamide after progression of metastatic …
Oct 17, 2022 · We aimed to evaluate the efficacy of continuing enzalutamide after progression in controlling metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel and …
LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, …
Enzalutamide (ENZA) and Lutetium-177-prostate-specific membrane antigen-617 (LuPSMA) both improve overall survival (OS) in mCRPC. Preclinical and clinical data suggest synergy for …
U.S. Food and Drug Administration Approval Summary: Enzalutamide …
The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
Adding 177Lu-PSMA-617 to Enzalutamide Improves Survival, QOL in mCRPC
6 days ago · Adding [177 Lu]Lu-PSMA-617 (LuPSMA; Pluvicto) to enzalutamide (Xtandi) significantly improved overall survival (OS) and quality of life (QOL) in patients with metastatic …
- Some results have been removed